JP2012501973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501973A5 JP2012501973A5 JP2011525298A JP2011525298A JP2012501973A5 JP 2012501973 A5 JP2012501973 A5 JP 2012501973A5 JP 2011525298 A JP2011525298 A JP 2011525298A JP 2011525298 A JP2011525298 A JP 2011525298A JP 2012501973 A5 JP2012501973 A5 JP 2012501973A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- peptide
- composition according
- mimic
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9402608P | 2008-09-03 | 2008-09-03 | |
| US61/094,026 | 2008-09-03 | ||
| PCT/US2009/055786 WO2010028089A2 (en) | 2008-09-03 | 2009-09-02 | Agents and methods for treatment of pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501973A JP2012501973A (ja) | 2012-01-26 |
| JP2012501973A5 true JP2012501973A5 (enExample) | 2012-08-30 |
| JP5801197B2 JP5801197B2 (ja) | 2015-10-28 |
Family
ID=41797838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525298A Expired - Fee Related JP5801197B2 (ja) | 2008-09-03 | 2009-09-02 | 痛みの治療に関する薬剤及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8324168B2 (enExample) |
| EP (1) | EP2334315B1 (enExample) |
| JP (1) | JP5801197B2 (enExample) |
| CN (1) | CN102202677A (enExample) |
| AU (1) | AU2009288088B2 (enExample) |
| CA (1) | CA2739416C (enExample) |
| WO (1) | WO2010028089A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009246316B2 (en) * | 2008-05-16 | 2014-06-19 | Nono Inc. | Treatment for epilepsy |
| CN102202677A (zh) | 2008-09-03 | 2011-09-28 | 阿尔伯维塔公司 | 治疗疼痛的活性剂和方法 |
| KR101886029B1 (ko) * | 2010-10-01 | 2018-08-07 | 호바 세라퓨틱스 에이피에스 | 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도 |
| EP3973981A1 (en) * | 2012-05-18 | 2022-03-30 | Janssen Biotech, Inc. | Huwentoxin-iv variants and methods of use |
| US10414808B2 (en) | 2012-05-18 | 2019-09-17 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| KR102166374B1 (ko) * | 2012-11-28 | 2020-10-15 | 노노 인코포레이티드 | Tat-nr2b9c의 동결건조된 제형 |
| CN103012597B (zh) * | 2012-12-31 | 2014-06-11 | 黑龙江大学 | 用于治疗骨质疏松症和止痛的OGP-CTx融合蛋白及编码该融合蛋白的核酸 |
| ES2841173T3 (es) | 2013-10-03 | 2021-07-07 | Janssen Biotech Inc | Variantes de Protoxina-II y métodos de uso |
| CA2946385A1 (en) * | 2014-04-22 | 2015-10-29 | Q-State Biosciences, Inc. | Diagnostic methods for neuronal disorders |
| MA41642A (fr) | 2015-03-03 | 2018-01-09 | Janssen Biotech Inc | Variants de protoxine ii et méthodes d'utilisation |
| US10048275B2 (en) | 2015-03-13 | 2018-08-14 | Q-State Biosciences, Inc. | Cardiotoxicity screening methods |
| TW201708249A (zh) | 2015-04-02 | 2017-03-01 | 健生生物科技公司 | 原毒素－ｉｉ變體及使用方法 |
| CN107312071B (zh) * | 2016-04-27 | 2018-11-06 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗方法 |
| WO2017185250A1 (zh) * | 2016-04-27 | 2017-11-02 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗方法 |
| CN107913395B (zh) * | 2016-10-10 | 2019-12-13 | 拜西欧斯（北京）生物技术有限公司 | 神经兴奋性损伤相关多肽在预防、缓解或治疗疼痛的用途 |
| EP3650460A4 (en) | 2017-07-05 | 2021-03-17 | Biocells (Beijing) Biotech Co., Ltd. | PHARMACEUTICAL SALT OF A POLYPEPTID AND ITS USES |
| EA202090802A1 (ru) * | 2017-09-30 | 2020-08-05 | Биоселз (Бейдзин) Биотек Ко., Лтд. | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью |
| CN109232745B (zh) * | 2018-09-18 | 2020-02-28 | 深圳瑞健生物科技有限公司 | 一种可通过血脑屏障的多肽 |
| CN109265558B (zh) * | 2018-09-18 | 2019-12-24 | 深圳瑞健生物科技有限公司 | 改进型齐考诺肽在制备药物中的应用 |
| CN109106942B (zh) * | 2018-09-18 | 2019-11-22 | 深圳瑞健生物科技有限公司 | 一种可通过血脑屏障的多肽在制备药物中的应用 |
| CN109265557B (zh) * | 2018-09-18 | 2019-12-24 | 深圳瑞健生物科技有限公司 | 一种齐考诺肽和tat肽的融合多肽在制备药物中的应用 |
| CN118307629A (zh) * | 2018-12-26 | 2024-07-09 | 思亲美有限公司 | 乙酰胆碱受体抑制肽及其用途 |
| CN111097037A (zh) * | 2020-01-16 | 2020-05-05 | 刘成龙 | 一种psd95-pdz1/2结构域抑制剂及其应用 |
| CN120958011A (zh) * | 2023-03-31 | 2025-11-14 | 青岛普美圣医药科技有限公司 | 具有延长的半衰期和提高的稳定性的多肽活性分子 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7760905B2 (en) | 1999-06-29 | 2010-07-20 | Digimarc Corporation | Wireless mobile phone with content processing |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| US7595297B2 (en) | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| US6759520B1 (en) | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
| US20080119412A1 (en) | 2003-12-23 | 2008-05-22 | Nono Inc. | Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins |
| US8003609B2 (en) * | 2004-03-30 | 2011-08-23 | The Hospital For Sick Children | Method for ameliorating pain by modification of NMDA receptors through inhibition of Src |
| US8633160B2 (en) | 2005-12-30 | 2014-01-21 | Nono Inc. | Small molecule inhibitors of PDZ interactions |
| US20080227684A1 (en) | 2005-12-30 | 2008-09-18 | Belmares Michael P | Small Molecule Inhibitors of PDZ Interactions |
| GB0610868D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| US20080019970A1 (en) * | 2006-07-07 | 2008-01-24 | Gorman James R | Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures |
| EP1884521A1 (en) | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| US20080124698A1 (en) | 2006-11-28 | 2008-05-29 | Ebensberger Jason M | Virtual coatings application system with structured training and remote instructor capabilities |
| AU2007340162B2 (en) * | 2006-12-29 | 2013-08-01 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
| DK2120987T3 (en) | 2007-03-02 | 2014-02-24 | Nono Inc | Treatment of stroke and other diseases without inhibiting N-type calcium channels |
| EP2144615A4 (en) * | 2007-04-06 | 2011-02-16 | Kai Pharmaceuticals Inc | METHOD OF USE OF GAMMA INHIBITOR COMPOUNDS FOR PAIN LIFTING |
| US20100204100A1 (en) * | 2007-04-19 | 2010-08-12 | The Johns Hopkins Univeristy | Biological agents active in central nervous system |
| US8008253B2 (en) | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| AU2009246316B2 (en) | 2008-05-16 | 2014-06-19 | Nono Inc. | Treatment for epilepsy |
| CN102202677A (zh) | 2008-09-03 | 2011-09-28 | 阿尔伯维塔公司 | 治疗疼痛的活性剂和方法 |
| AU2010327936B2 (en) | 2009-12-11 | 2015-08-20 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
-
2009
- 2009-09-02 CN CN2009801431948A patent/CN102202677A/zh active Pending
- 2009-09-02 WO PCT/US2009/055786 patent/WO2010028089A2/en not_active Ceased
- 2009-09-02 CA CA2739416A patent/CA2739416C/en active Active
- 2009-09-02 JP JP2011525298A patent/JP5801197B2/ja not_active Expired - Fee Related
- 2009-09-02 EP EP09812187.4A patent/EP2334315B1/en active Active
- 2009-09-02 AU AU2009288088A patent/AU2009288088B2/en not_active Ceased
- 2009-09-03 US US12/553,096 patent/US8324168B2/en not_active Expired - Fee Related
-
2012
- 2012-11-13 US US13/675,893 patent/US8748387B2/en active Active
-
2014
- 2014-05-09 US US14/274,355 patent/US9365620B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602824A (en) | Sparc binding peptides and uses thereof | |
| JP2015517488A5 (enExample) | ||
| WO2007081975A3 (en) | Method of treating multiple sclerosis | |
| WO2011107653A8 (en) | Use of levodopa, carbidopa and entacapone for treating parkinson's disease | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| JP2015518818A5 (enExample) | ||
| WO2008087190A3 (en) | Use of peptides in combination with surgical intervention for the treatment of obesity | |
| NZ592510A (en) | HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same | |
| NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| NZ623495A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| TW200744642A (en) | Novel peptides for use in the treatment of obesity | |
| MX2023012271A (es) | Medicina terapeutica para enfermedades fibrosas. | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| WO2008087186A3 (en) | Peptides for use in the treatment of obesity | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
| NZ602693A (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| WO2008087188A3 (en) | Peptides for use in the treatment of obesity | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| NZ591408A (en) | Paracetamol and Calcium carbonate composition | |
| PH12014500191A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| EP3026057A3 (en) | Compositions for prevention and treatment of neurodegenerative diseases | |
| JP2016515137A5 (enExample) |